Summary
The effect of a five day pretreatment with phenformin (3 x 50 mg daily) on hepatic metabolism was studied in six healthy volunteers. Arterial and hepatic venous concentrations of substrates and hepatic blood flow were estimated during a basal period and during a low-dose lactate infusion (0,03 mmol · kg−1· min−1). The results have been compared with those obtained from untreated normal subjects in a previous study (16). During the baseline period arterial concentration of alanine and the hepatic venous concentration ratios of alanine: pyruvate andβ-hydroxybutyrate: acetoacetate were significantly increased with phenformin treatment, while the balances of carbon dioxide and glucose and the fractional extraction of alanine were decreased compared to the values obtained in untreated subjects. During lactate infusion mean arterial lactate concentration was significantly increased and hepatic lactate extraction was decreased compared to untreated persons under the same conditions. In the phenformin-treated group lactate infusion resulted in hepatic output of pyruvate and the hepatic glucose balance remained unchanged compared to baseline. Since the rate of hepatic blood flow was not increased during lactate infusion a significantly smaller glucose output and lactate uptake was obtained with phenformin. These findings support the present view that the hypoglycaemic effect of biguanides is due, at least in part, to inhibition of hepatic gluconeogenesis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Butterfield, W.J.H., Whichelow, M.J.: Effect of diet, sulphonylureas and phenformin on peripheral glucose uptake in diabetes and obesity. Lancet1968 II, 785–793
Tyberghein, J.M., Williams, R.H.: Metabolic effects of phenethylbiguanide, a new hypoglycemic compound. Proc. Soc. Exp. Biol. Med.96, 29–34 (1957)
Patrick, S.J.: Effect of phenformin and hypoglycin on gluconeogenesis of rat tissues. Can. J. Biochem.44, 27–33 (1966)
Altschuld, R.A., Krüger, F.A.: Inhibition of hepatic gluconeogenesis in guinea pig by phenformin. Ann. N.Y. Acad. Sci.148, 612–622 (1968)
Toews, C.J., Kyner, J.L., Connon, J.J.: The effect of phenformin on gluconeogenesis in isolated perfused rat liver. Diabetes19, 368 (1970)
Creutzfeldt, W., Willms, B., Caspary, W.: The mechanism of action of the blood glucose lowering biguanides. In: R.R. Rodriguez, J. Vallance-Owen (Eds.): Diabetes, (Proc. 7th Congr. Int. Diab. Fed.), pp. 708–719. Amsterdam: Excerpta Medica 1971
Haeckel, R., Haeckel, H.: Inhibition of gluconeogenesis from lactate by phenethyl-biguanide in the perfused guinea pig liver. Diabetologia8, 117–124 (1972)
Tranquada, R.E., Kleemann, C., Brown, J.: Some effects of phenethylbiguanide on human hepatic metabolism as measured by hepatic vein catheterization. Diabetes9, 207–214 (1960)
Beringer, A., Hupka, K., Mosslacher, K., Moser, K., Wenger, R.: Zur Beeinflussung des menschlichen Diabetes mit Insulin, blutzuckersenkenden Sulfonamiden sowie Biguaniden. Wien Med. Wochenschr.108, 639–644 (1958)
Searle, G.L., Cavalieri, R.R.: Glucose kinetics before and after phenformin in the human subject. Ann. N. Y. Acad. Sci.148, 734–742 (1968)
Kreisberg, R.A.: Glucose metabolism in normal and obese subjects. Effect of phenformin. Diabetes17, 481–487 (1968)
Wick, A.N., Stewart, Ch. J., Serif, G.S.:Tissue distribution of C14-labeled betaphenethyl-biguanide. Diabetes9, 163–167 (1960)
Beckmann, R.: Resorption, Verteilung im Gewebe und Ausscheidung von 1-Butyl-biguanid14C -hydrochlorid. Drug Res.15, 761–764 (1965)
Wahren, J., Felig, P., Ahlberg, G., Jorfeldt, L.: Glucose metabolism during leg exercise in man. J. Clin. Invest.50, 2715–2725 (1971)
Dietze, G., Wicklmayr, M., Hepp, K.D., Bogner, W., Mehnert, H., Czempiel, H., Henftling, H.G.: On gluconeogenesis of human liver. Accelerated hepatic glucose formation induced by increased precursor supply. Diabetologia12, 555–561 (1976)
Statist. Bull. Metrop. Life Insur. Co.:40, Nov.–Dec. (1959)
Empfehlungen der Deutschen Gesellschaft für klinische Chemie. J. Clin. Chem. Clin. Biochem.14, 182–192 (1972)
World Medical Association Declaration of Helsinki Br. Med. J.1964 II, 177-180
Boberg, J.: Heparin-released blood plasma lipoprotein lipase activity in patients with hyperlipoproteinemia. Acta Med. Scand.191, 97–105 (1972)
Schmitz-Feuerhake, J., Tägder, K., Fröhlich, H., Pixberg, H.U., Haubold, E.: Die Bestimmung der spezifischen Durchblutung von Leber, Milz, und Niere durch Inhalation von radioaktivem Xenon. In: P. M van Vaerenbergh, H.W. Pabst, G. Hör (Eds.): Nuklearmedizin. (9th Ann. Meet. Soc. Nucl. Med., Antwerpen 1971), pp. 264–268. New York: Schattauer Verlag 1973
Dietze, G., Wicklmayr, M., Czempiel, H., Henftling, H.G., Mehnert, H.: On the analysis of the hepatic-venous133xenon-clearance after the application of the gas by inhalation. Klin. Wochenschr.53, 638–640 (1975)
Zierler, K.L.: Theory of the use of arteriovenous concentration differences for measuring metabolism in steady and nonsteady states. J. Clin. Invest.40, 2111–2131 (1961)
Snedecor, G.W., Cochran, W.G.: Statistical methods, 6th edition. Ames, Iowa: Iowa State University Press 1967
Ungar, G., Freedman, L., Shapiro, S.L.: Pharmacological studies on a new hypoglycemic drug. Proc. Soc. Exp. Biol. Med.95, 190–194 (1957)
Hollunger, G.: Guanidines and oxidative phosphorylation. Acta Pharmacol. Toxicol. (Kbh.)11 (Suppl. 1), 1–84 (1955)
Schäfer, G.: Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes. Biochem. Pharmacol.25, 2015–2024 (1976)
Wick, A.N., Larson, E., Serif, G.S.: A site of action of phenethylbiguanide, a hypoglycemic compound. J. Biol. Chem.233, 292–296 (1958)
Steiner, D.F., Williams, R.H.: Respiratory inhibition and hypoglycemia by biguanides and decamethylene-diguanide. Biochim. Biophys. Acta93, 279–283 (1964)
Bücher, Th., Klingenberg, M.: Wege des Wasserstoffs in der lebendigen Organisation. Angew. Chem. (Engl.)70, 552–570 (1958)
Marliss, E.B., Aoki, T.T., Toews, C.J., Felig, P., Connon, J.J., Kyner, J., Huckabee, W.E., Cahill, G.F.: Amino acid metabolism in lactic acidosis. J. A. M. A.52, 474–481 (1972)
Fajans, S.S., Moorhouse, J.A., Doorenbos, H., Louis, L.H., Conn, J.W.: Metabolic effects of phenethylbiguanide in normal subjects and in diabetic patients. Diabetes9, 194–201 (1960)
Dietze, G., Wicklmayr, M., Braun, S., Hepp, K.D., Mehnert, H.: Untersuchungen zur Wirkung von Biguaniden am Gesunden. Die Glukoseutilisation des Muskels unter dem Einfluß von Phenformin. Verh. Dtsch. Ges. Inn. Med.80, 1283–1286 (1974)
Schimassek, H.: Metabolite des Kohlenhydratstoffwechsels der isoliert perfundierten Rattenleber. Biochem. Z.336, 460–465 (1963)
Hems, R., Ross, B.D., Berry, M.N., Krebs, H.A.: Gluconeogenesis in the perfused rat liver. Biochem. J.101, 284–292 (1966)
Kramer, K., Driessen, G., Brechteisbauer, H.: Lactate elimination and O2-consumption of the liver in narcoticized dogs. Pfluegers Arch.330, 195–202 (1971)
Tranquada, R.E., Bernstein, S., Martin, H.E.: Irreversible lactic acidosis associated with phenformin therapy. J. A. M. A.184, 43–47 (1963)
Buess, H.J., Mihatsch, M.J., Wunderlich, P., Berger, W.: tatazidose beim Diabetes mellitus. Schweiz. Rundschau Med.65, 406–410 (1976)
Wittmann, P., Haslbeck, M., Bachmann, W., Mehnert, H.: Lactic acidosis in diabetics on biguanides. Dtsch. Med. Wochenschr.102, 5–10 (1977)
Owen, O.E., Felig, P., Morgan, A.P., Wahren, J., Cahill, G.F., Jr.: Liver and kidney metabolism during prolonged starvation. J. Clin. Invest.48, 574–583 (1969)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dietze, G., Wicklmayr, M., Mehnert, H. et al. Effect of phenformin on hepatic balances of gluconeogenic substrates in man. Diabetologia 14, 243–248 (1978). https://doi.org/10.1007/BF01219423
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01219423